A Dilemma in the Glycosaminoglycan‐Based Therapy: Synthetic or Naturally Unique Molecules?
Identifieur interne : 001A08 ( Main/Exploration ); précédent : 001A07; suivant : 001A09A Dilemma in the Glycosaminoglycan‐Based Therapy: Synthetic or Naturally Unique Molecules?
Auteurs : Vitor H. Pomin [Brésil]Source :
- Medicinal Research Reviews [ 0198-6325 ] ; 2015-11.
Abstract
Glycosaminoglycans (GAGs) are widely explored in the biomedical market as functional ingredients in pharmaceutical or nutraceutical preparations. This extensive application of GAGs is justified by their multiple activities across several systems including, but not limited to, coagulation, thrombosis, inflammation, cancer, angiogenesis, cell differentiation, tissue repair, and microbial infections. Therapeutic GAGs are commonly extracted from mammalian tissues. Although functional in diverse systems, mammalian GAGs present serious downsides in therapy such as contamination risk from the mammalian tissues. In order to overcome some of the downsides, two new GAG sources have been appearing as alternatives to the mammalian‐derived molecules. They are the synthetic GAGs and those extracted from nonmammalian origins such as invertebrate animals. This report overviews the general aspects of each GAG alternative and compares critically their pros and cons attributes in light of the prospects for the future of GAG‐based therapy.
Url:
DOI: 10.1002/med.21356
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002422
- to stream Istex, to step Curation: 002422
- to stream Istex, to step Checkpoint: 000152
- to stream Main, to step Merge: 001A13
- to stream Main, to step Curation: 001A08
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Dilemma in the Glycosaminoglycan‐Based Therapy: Synthetic or Naturally Unique Molecules?</title><author><name sortKey="Pomin, Vitor H" sort="Pomin, Vitor H" uniqKey="Pomin V" first="Vitor H." last="Pomin">Vitor H. Pomin</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:98F11CE3AE1C22A475E31377B9A05D3C9CEE7731</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1002/med.21356</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-ZH17RB53-4/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002422</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002422</idno><idno type="wicri:Area/Istex/Curation">002422</idno><idno type="wicri:Area/Istex/Checkpoint">000152</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000152</idno><idno type="wicri:doubleKey">0198-6325:2015:Pomin V:a:dilemma:in</idno><idno type="wicri:Area/Main/Merge">001A13</idno><idno type="wicri:Area/Main/Curation">001A08</idno><idno type="wicri:Area/Main/Exploration">001A08</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">A Dilemma in the Glycosaminoglycan‐Based Therapy: Synthetic or Naturally Unique Molecules?</title><author><name sortKey="Pomin, Vitor H" sort="Pomin, Vitor H" uniqKey="Pomin V" first="Vitor H." last="Pomin">Vitor H. Pomin</name><affiliation wicri:level="3"><country xml:lang="fr">Brésil</country><wicri:regionArea>Program of Glycobiology, Institute of Medical Biochemistry Leopoldo de Meis, University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, RJ, 21941‐913, Rio de Janeiro</wicri:regionArea><placeName><settlement type="city">Rio de Janeiro</settlement><region type="state">État de Rio de Janeiro</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Brésil</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Medicinal Research Reviews</title><title level="j" type="alt">MEDICINAL RESEARCH REVIEWS</title><idno type="ISSN">0198-6325</idno><idno type="eISSN">1098-1128</idno><imprint><biblScope unit="vol">35</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1195">1195</biblScope><biblScope unit="page" to="1219">1219</biblScope><biblScope unit="page-count">25</biblScope><date type="published" when="2015-11">2015-11</date></imprint><idno type="ISSN">0198-6325</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0198-6325</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Glycosaminoglycans (GAGs) are widely explored in the biomedical market as functional ingredients in pharmaceutical or nutraceutical preparations. This extensive application of GAGs is justified by their multiple activities across several systems including, but not limited to, coagulation, thrombosis, inflammation, cancer, angiogenesis, cell differentiation, tissue repair, and microbial infections. Therapeutic GAGs are commonly extracted from mammalian tissues. Although functional in diverse systems, mammalian GAGs present serious downsides in therapy such as contamination risk from the mammalian tissues. In order to overcome some of the downsides, two new GAG sources have been appearing as alternatives to the mammalian‐derived molecules. They are the synthetic GAGs and those extracted from nonmammalian origins such as invertebrate animals. This report overviews the general aspects of each GAG alternative and compares critically their pros and cons attributes in light of the prospects for the future of GAG‐based therapy.</div></front></TEI><affiliations><list><country><li>Brésil</li></country><region><li>État de Rio de Janeiro</li></region><settlement><li>Rio de Janeiro</li></settlement></list><tree><country name="Brésil"><region name="État de Rio de Janeiro"><name sortKey="Pomin, Vitor H" sort="Pomin, Vitor H" uniqKey="Pomin V" first="Vitor H." last="Pomin">Vitor H. Pomin</name></region><name sortKey="Pomin, Vitor H" sort="Pomin, Vitor H" uniqKey="Pomin V" first="Vitor H." last="Pomin">Vitor H. Pomin</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A08 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A08 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:98F11CE3AE1C22A475E31377B9A05D3C9CEE7731
|texte= A Dilemma in the Glycosaminoglycan‐Based Therapy: Synthetic or Naturally Unique Molecules?
}}
| This area was generated with Dilib version V0.6.33. |  |